Keystone Symposia

Embassy Suites by Hilton Denver Downtown Floorplan

This meeting took place in 2022



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics (E2)


Organizer(s) Bridget Wagner, Neil O. Carragher, Jeremy Jenkins and Laura Kiessling
May 22—25, 2022
Embassy Suites by Hilton Denver Downtown • Denver, CO USA
Abstract Deadline: Mar 14, 2022
Scholarship Deadline: Mar 14, 2022
Discounted Registration Deadline: Mar 22, 2022

Sponsored by AbbVie Inc., BioLegend, Inc., Genmab A/S, Merck & Co., Inc. and PhenoVista Biosciences

Summary of Meeting:
PDD as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This meeting will bring together researchers performing or interested in phenotypic drug discovery (PDD) from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. The previous two PDD Keystone Symposia, in 2016 and 2019, were tremendously received, and we have determined that there is ample enthusiasm for hosting another Keystone Symposium on this evolving topic. Our goals in this meeting are to 1) share information and best practices in new PDD technologies, biological models, and human disease areas; 2) foster collaborative discussions across academia and industry; and 3) address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). We anticipate that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, May 22 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, May 25 with a closing plenary session from 17:00 to 19:00, followed by a social hour. We recommend return travel on Thursday, May 26 in order to fully experience the meeting.

SUNDAY, MAY 22

16:00—20:00
Arrival and Registration

Crystal Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Crystal Foyer

MONDAY, MAY 23

07:00—08:00
Breakfast

At Individual Hotel
08:00—09:00
Welcome and Keynote Address (8am Start)

Crystal Ballroom
* Bridget Wagner, Broad Institute, USA
Session Chair

Anne E. Carpenter, Broad Institute of Harvard and MIT, USA
Cell Painting Powers Next Generation Phenotypic Drug Discovery

09:00—11:00
Applications of Modern Computational Techniques to PDD (9am Start)

Crystal Ballroom
* Paul A. Clemons, Broad Institute of Harvard and MIT, USA
Session Chair

Ci Chu, Insitro, USA
Machine Learning Driven TSC Disease Modeling and Reversion Screening in an iPSC Derived Disease Model

Coffee Break

* Yolanda Chong, Recursion Pharmaceuticals, USA
Integrating Imaging with Machine Learning in Phenotypic Screening

Christian Meyer, University of Colorado Boulder, USA
A Consensus Framework for Calculating Drug Synergy in Phenotypic Assays

Asako Tsubouchi, ThinkCyte Inc, Japan
Short Talk: Novel Machine Vision-based Cytometry Approach for High-throughput Pooled Phenotypic CRISPR Screening

11:15—17:00
On Own for Lunch

11:15—13:00
Poster Setup

Crystal Ballroom
13:00—22:00
Poster Viewing

Crystal Ballroom
15:00—16:30
Workshop: AI Enabling of Phenotypic Drug Discovery (3pm Start)

Serena Silver, Fulcrum Therapeutics, USA
Remote Presentation: Revolutionizing Drug Discovery for Genetically Defined Disease using Disease Relevant Cell Types and High-dimensional Phenotypic Datasets

Johannes Wilbertz, Ksilink, France
Machine Learning-aided Multidimensional Phenotyping of Parkinson's Disease Patient Stem Cell-derived Midbrain Dopaminergic Neurons

Denise V. Barrault, Exscientia AI Ltd., UK
XcellomicsTM: An AI-driven Phenomics Drug Discovery Collaboration

* Douglas Selinger, Plex Research, USA
Plex: A Novel form of Artificial Intelligence (AI) for the Identification of Compound Targets and Mechanism of Action

Gregory Way, University of Colorado Anschutz, USA
Predicting Drug Polypharmacology from Cell Morphology Readouts using Variational Autoencoder Latent Space Arithmetic

Daniel Krentzel, Institut Pasteur, France
Deep Learning for Antibiotic Target Identification from High-Throughput Images

16:30—17:00
Coffee Available

Crystal Foyer
17:00—19:00
Phenotypic Approaches to Tackling Infectious Disease (5pm Start)

Crystal Ballroom
* Laura L. Kiessling, Massachusetts Institute of Technology, USA
Bacterial Glycan Assembly: A New Approach to Antibiotics Discovery

Jason K. Sello, University of California, San Francisco, USA
Discovery of Novel Small Molecules to Target Tuberculosis

* Marc P. Windisch, Institut Pasteur Korea, South Korea
Phenotypic Screening of FDA-Approved Drugs Using Middle East Respiratory Syndrome Coronavirus Identifies Potential Therapeutic Options for COVID-19

Floriano P. Silva-Jr, Fiocruz, Brazil
Short Talk: SchistoSPro: An Innovative and Cost-effective Platform to Identify New Drugs against Adult Schistosome Worms

Brian Y. Feng, Calico Labs, USA
Short Talk: Morphological Characterization of Antibiotic Combinations

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Crystal Foyer
19:30—22:00
Poster Session 1

Crystal Ballroom

TUESDAY, MAY 24

07:00—08:00
Breakfast

At Individual Hotel
07:30—08:00
Poster Setup

Crystal Ballroom
08:00—19:00
Poster Viewing

Crystal Ballroom
08:00—11:00
Novel Chemistry to Enable PDD (8am Start)

Crystal Ballroom
Raphaël Rodriguez, Institut Curie, France
Novel Chemical Tools to Discover Intracellular Targets

Amit Choudhary, Harvard Medical School, USA
Phosphorylation-inducing Chimeric Small Molecules

Coffee Break

* Susanne Müller-Knapp, Structural Genomics Consortium - Frankfurt, Germany
Open-Source Chemical Probes for Understanding Cellular Phenotypes

* Seung Bum Park, Seoul National University, South Korea
Targeted Protein Upregulation Potentiates STING Agonist Immunotherapy

Zita Hubler, Case Western Reserve University School of Medicine, USA
Short Talk: Remyelinating Therapies and the Cholesterol Biosynthesis Pathway: An Unexpected Role for 8,9-unsaturated Sterols

Ctibor Škuta, IMG CAS, Czech Republic
Short Talk: Probes & Drugs Portal in 2022: A Hub for the Integration of High-quality Bioactive Compound Sets

11:00—12:30
Lunch

Crystal Foyer
12:00—14:30
Poster Session 2

Crystal Ballroom
16:30—17:00
Coffee Available

Crystal Foyer
17:00—19:00
Innovative Cell and Animal Models to Advance PDD (5pm Start)

Crystal Ballroom
* Laura L. Kiessling, Massachusetts Institute of Technology, USA
Session Chair

* Bridget Wagner, Broad Institute, USA
A Human Pancreatic Islet Cell Culture System for Phenotypic Screening

Matthäus Mittasch, Dewpoint Therapeutics GmbH, Germany
Assaying Small Molecule Partitioning into Biomolecular Condensates

Emily G. Tippetts, University of Utah, USA
Short Talk: Chemical Screening in Zebrafish Models of Leigh Syndrome

Sietske Bakker, Genmab, Netherlands
Short Talk: Quantification of T-cell Proliferation in High Throughput Screening

19:00—21:00
On Own for Dinner


WEDNESDAY, MAY 25

07:00—08:00
Breakfast

At Individual Hotel
08:00—11:15
Systems Biology Approaches to Chemical Biology (8am Start)

Crystal Ballroom
Paul A. Clemons, Broad Institute of Harvard and MIT, USA
Chemical Biology Applications of Pathway and Network Approaches to Human Disease

Taran S. Gujral, Fred Hutchinson Cancer Research Center, USA
Systems Pharmacology and Machine Learning Identifies Druggable Cancer Cell-stroma Interactions

Coffee Break

* Jeremy Jenkins, Novartis Institutes for BioMedical Research, USA
Systematic Assembly of a Chemogenetic Library and MOA Elucidation

Sujatha M. Gopalakrishnan, AbbVie, Inc., USA
Small Molecule Phenotypic Screening Efforts at AbbVie to Identify Novel Biology and Druggable Targets

Jessica Lacoste, University of Toronto, Canada
Short Talk: Pervasive Mislocalization of Pathogenic Coding Variants Underlying Human Diseases

* Jayme L. Dahlin, NCATS, USA
Short Talk: High-content Biological Annotation of Chemical Space with the NCATS ASPIRE Initiative

Alex Federation, Talus Bio, USA
Short Talk: Profiling the DNA Regulome to Discover Transcription Factors Inhibitors

11:15—17:00
On Own for Lunch

15:00—16:30
Career Roundtable

Crystal Ballroom
Jason K. Sello, University of California, San Francisco, USA

Deborah M. Rothman, Merck & Co. Inc, USA

16:30—17:00
Coffee Available

Crystal Foyer
17:00—18:45
Advances in Approaches to Understand Mechanism of Action (5pm Start)

Crystal Ballroom
* Neil O. Carragher, University of Edinburgh, UK
Accelerating PDD through Multiparametric High Content Imaging and Pathway Profiling across Genetically Distinct Cell Panels

* John G. Moffat, Genentech, Inc., USA
You Can't Always Get What You Want, But... : From Pathway Screening to Target Identification

Deborah M. Rothman, Merck & Co. Inc, USA
Novel Mechanisms Emerging from Target Agnostic Screens

Nigel Beaton, Biognosys, Switzerland
Short Talk: Limited Proteolysis as a Proteomics Tool for Target Deconvolution and Mechanistic Insights – A Test Case

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (6:45pm Start)

Crystal Ballroom
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Crystal Foyer

THURSDAY, MAY 26

08:00—08:00
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

AbbVie Inc. BioLegend, Inc.
Genmab A/S Merck & Co., Inc.
Moderna PhenoVista Biosciences

We gratefully acknowledge additional support from these exhibitors at this conference:

10x Genomics BioLegend, Inc.
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1 R13 TR004225-01

Funding for this conference was made possible (in part) by 1 R13 TR004225-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genentech, Inc.


Insitro


Merck & Co., Inc.


Novartis Institutes for BioMedical Research


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: John Monson, Director of Corporate Relations, Email: johnm@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Josh May, Director, Technology and Digital Media, Email: joshuam@keystonesymposia.org,
Phone:+1 970-262-1179